Skip to main content
NSE - SMEListed
Medicamen Organics Limited Logo

Medicamen Organics Limited IPO

Medicamen Organics Limited IPO

IPO Date :
Issue Price :
Allotment Date :
Listing Date :
List Price :
Lot Size:
Subscription:
Listed Price: ₹ 137.85 (+305.44%)

The public market debut of Medicamen Organics Limited's was completed on 28-06-2024 with its listing on the NSE exchange. The IPO process raised 31,00,000 Shares in total capital, consisting of 31,00,000 Shares in new equity.

The offering featured a price range of ₹32 to ₹34 and minimum application size of 4000 shares. Investor response during the subscription period from 21-06-2024 to 25-06-2024 influenced the final allotment ratios across investor categories.

Final allotment was announced on 26-06-2024, distributing shares to successful subscribers. The listing established a continuous market for the company's shares, enabling liquidity, valuation transparency, and broader investor participation.

Medicamen Organics IPO Details
Lot(s) Distribution

Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.

IPO Reservation
Medicamen Organics IPO Key Performance Indicator
Company Financials ( in ₹ Lakhs )

Medicamen Organics IPO About Company

Medicamen Organics Limited, founded in 1995, is a trusted pharmaceutical company specializing in the development, manufacturing, and distribution of a wide range of pharmaceutical dosages, including tablets, capsules, syrups, ointments, gels, and dry powders. Catering to both government and private sectors as a contract manufacturer, the company offers 84 products across various therapeutic categories, such as antibacterials, antifungals, antidiabetics, antihypertensives, and multivitamin preparations. Medicamen Organics has a strong domestic presence and exports to multiple international markets, including Africa, CIS, and Southeast Asia. The company operates two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, spanning 21,536 square feet. With partnerships with 38 domestic contract manufacturers and 12 merchant exporters, the company employed 116 people as of September 30, 2023, ensuring high-quality production and global reach.


Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."


Medicamen Organics IPO Strength Factors

  1. Strong Leadership: Medicamen Organics Limited is led by experienced promoters and a skilled management team, ensuring strategic growth and effective decision-making.
  2. Trusted Customer Relationships: The company has built long-standing relationships with its customers, driving consistent demand and business stability.
  3. Efficient Operations: A highly capable operational team ensures high productivity and quality manufacturing, reinforcing the company’s reliability in the pharmaceutical industry.

Medicamen Organics IPO Risk Factors

  1. Regulatory Challenges: The company needs multiple approvals and licenses to operate. Any delays or failures in obtaining them could impact business activities.
  2. Raw Material Cost Fluctuations: Price changes in raw materials can increase production costs and affect profitability.
  3. Customer Dependence: Relying on a few major customers means losing one could significantly impact revenue and overall financial stability.

Medicamen Organics IPO Lead Manager(s)

  • GYR Capital Advisors Private Limited

Medicamen Organics IPO Promoter(s)

  1. Mr. Bal Kishan Gupta

Medicamen Organics IPO Company Details

Medicamen Organics Limited
Phone:
address:

Medicamen Organics IPO Registrar

Kfin Technologies Limited
Name:
Phone:

Medicamen Organics IPO FAQs